drugset / Trial / NCT01660802

Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)

NCT01660802 ↗

Phase 3 Completed 262 enrolled Allergan
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the safety and efficacy of 700 μg dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in patients with macular edema in a 6 month double-blind period versus sham followed by a 2 month open label period.

Timeline

Start
2012-09-04
Primary completion
2014-03-31
Completion
2014-05-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 700 ug Intravitreal

Indications